Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",leukocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000027,white blood cell count,,,,3.2,x 1000 cells/ul,0.5196,0.9,MMO:0000146,automated blood cell counting method,,0.0,,,,,control condition,104835,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",leukocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000027,white blood cell count,,,,3,x 1000 cells/ul,0.2309,0.4,MMO:0000146,automated blood cell counting method,,0.0,,,,,control condition,104836,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000041,red blood cell distribution width-coefficient of variation,,,,19.6,%,0.8083,1.4,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104915,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000041,red blood cell distribution width-coefficient of variation,,,,16,%,0.6928,1.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104916,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000025,red blood cell count,,,,8.9,x 10E6 cells/ul,0.1732,0.3,MMO:0000146,automated blood cell counting method,,0.0,,,,,control condition,104839,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000025,red blood cell count,,,,8.1,x 10E6 cells/ul,0.1732,0.3,MMO:0000146,automated blood cell counting method,,0.0,,,,,control condition,104840,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000038,mean corpuscular volume,,,,47.2,fl,0.8083,1.4,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104875,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000038,mean corpuscular volume,,,,51.4,fl,0.6351,1.1,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104876,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000037,hematocrit,,,,42.1,%,0.9238,1.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104859,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000037,hematocrit,,,,41.7,%,0.9238,1.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104860,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood glucose amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000046,blood glucose level,,,,129.6,mg/dl,4.1569,7.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104967,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood glucose amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000046,blood glucose level,,,,108,mg/dl,12.4708,21.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104968,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",leukocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000032,blood monocyte count,,,,0.4,x 1000 cells/ul,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104903,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",leukocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000032,blood monocyte count,,,,0.1,x 1000 cells/ul,0.0,0.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104904,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",lymphocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000031,blood lymphocyte count,,,,1.7,x 1000 cells/ul,0.5196,0.9,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104899,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",lymphocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000031,blood lymphocyte count,,,,1.8,x 1000 cells/ul,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104900,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",eosinophil quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000033,blood eosinophil count,,,,0.04,x 1000 cells/ul,0.0346,0.06,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104907,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",eosinophil quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000033,blood eosinophil count,,,,0.03,x 1000 cells/ul,0.0,0.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104908,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000290,mean corpuscular hemoglobin,,,,16.2,pg,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104879,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000290,mean corpuscular hemoglobin,,,,17.7,pg,0.2309,0.4,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104880,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood aspartate transaminase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000580,blood aspartate aminotransferase activity level,,,,124.3,U/l,5.6003,9.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104931,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood aspartate transaminase amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000580,blood aspartate aminotransferase activity level,,,,100.5,U/l,5.658,9.8,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104932,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood alanine transaminase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000574,blood alanine aminotransferase activity level,,,,43.7,U/l,3.2909,5.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104927,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood alanine transaminase amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000574,blood alanine aminotransferase activity level,,,,35.8,U/l,6.6395,11.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104928,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood alkaline phosphatase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000576,blood alkaline phosphatase activity level,,,,69.3,U/l,2.5981,4.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104939,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood alkaline phosphatase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000576,blood alkaline phosphatase activity level,,,,38,U/l,5.4271,9.4,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104940,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",eosinophil quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000369,blood eosinophil count to total leukocyte count ratio,,,,1,%,0.5196,0.9,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104895,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",eosinophil quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000369,blood eosinophil count to total leukocyte count ratio,,,,1,%,0.0577,0.1,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104896,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",lymphocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000371,blood lymphocyte count to total leukocyte count ratio,,,,50.7,%,4.0415,7.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104887,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",lymphocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000371,blood lymphocyte count to total leukocyte count ratio,,,,57.8,%,4.5611,7.9,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104888,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",monocyte quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000374,blood monocyte count to total leukocyte count ratio,,,,3.3,%,0.4041,0.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104891,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",monocyte quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000374,blood monocyte count to total leukocyte count ratio,,,,3.6,%,0.4619,0.8,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104892,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood total protein amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000028,blood protein measurement,,,,640,g/dl,7.5056,13.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104955,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood total protein amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000028,blood protein measurement,,,,677,g/dl,16.7432,29.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104956,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood albumin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000549,blood albumin level,,,,339,g/dl,5.1962,9.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104959,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood albumin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000549,blood albumin level,,,,373,g/dl,12.7017,22.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104960,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood globulin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0002398,blood globulin level,,,,301,g/dl,6.3509,11.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104963,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood globulin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0002398,blood globulin level,,,,305,g/dl,4.6188,8.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104964,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood creatine kinase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0002242,blood creatine kinase activity level,,,,41,IU/l,0.5774,1.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104983,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood creatine kinase amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0002242,blood creatine kinase activity level,,,,34.5,IU/l,3.2332,5.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104984,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood gamma-glutamyltransferase amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0002239,blood gamma-glutamyltransferase activity level,,,,1.3,U/l,0.3464,0.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104935,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood gamma-glutamyltransferase amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0002239,blood gamma-glutamyltransferase activity level,,,,1.8,U/l,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104936,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet quantity,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000029,platelet count,,,,1004,x 1000 cells/ul,80.5981,139.6,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104863,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet quantity,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000029,platelet count,,,,964.3,x 1000 cells/ul,62.2384,107.8,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104864,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,3443,g/dl,23.6714,41.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104883,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,3433,g/dl,12.7017,22.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104884,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0001350,platelet distribution width,,,,8.9,fl,0.5774,1.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104919,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0001350,platelet distribution width,,,,9.8,fl,0.4041,0.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104920,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood bilirubin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000048,plasma direct bilirubin level,,,,0.3,umol/l,0.1155,0.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104947,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood bilirubin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000048,plasma direct bilirubin level,,,,0.4,umol/l,0.1155,0.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104948,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood bilirubin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000047,plasma indirect bilirubin level,,,,-0.6,umol/l,0.1155,0.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104951,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood bilirubin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000047,plasma indirect bilirubin level,,,,-0.2,umol/l,0.1732,0.3,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104952,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0001348,mean platelet volume,,,,8.1,fl,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104867,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0001348,mean platelet volume,,,,8.7,fl,0.2309,0.4,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104868,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0003232,red blood cell distribution width- standard deviation,,,,28,%,0.9815,1.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104911,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",erythrocyte size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0003232,red blood cell distribution width- standard deviation,,,,25.6,%,0.6928,1.2,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104912,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0003233,platelet-large cell ratio,,,,16.5,%,1.4434,2.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104921,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0003233,platelet-large cell ratio,,,,11.7,%,2.1939,3.8,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104923,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0003233,platelet-large cell ratio,,,,16.1,%,1.6166,2.8,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104924,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000026,blood hemoglobin level,,,,1450,g/dl,40.4145,70.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104855,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood hemoglobin amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000026,blood hemoglobin level,,,,1450,g/dl,40.4145,70.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104856,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood urea nitrogen amount,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0000049,blood urea nitrogen level,,,,810,mg/dl,28.8675,50.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104971,control condition 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",blood urea nitrogen amount,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0000049,blood urea nitrogen level,,,,920,mg/dl,57.735,100.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104972,control condition